Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

  • 01:25

    Myeloma Crowd Radio: Dr. Kenneth Anderson, MD, PhD, Dana-Farber Cancer Institute

    in Health

    The advances found for multiple myeloma over the past two decades have been extroardinary. Much has been learned, and much has been accomplished with new treatment developments and arguably more discoveries than other cancers in the same time period. The past is impressive for this complex cancer, but there is more work to do. Dr. Ken Anderson helped lead the way for the discovery of new developments over a prestigious career of 40 years. He shares with us a brief look back and what he sees for the road ahead towards a cure.

    Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. 

    Thanks to our episode sponsor, Takeda Oncology

  • 01:20

    Myeloma Crowd Radio: Dr. Ola Landgren, MD, PhD, Memorial Sloan Kettering

    in Health

    New developments for multiple myeloma are happening at an ever increasing pace. Dr. Ola Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and heavily involved in the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Working Group meeting as well as an ASH preview (for the upcoming December conference). He will also share up and coming clinical trials at Memorial Sloan Kettering Cancer Center to incorporate these new treatments into clinical practice. Learn what new drugs will be available and how they can be used in the myeloma clinic. 

  • 01:13

    Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center

    in Health

    What happened at this year's American Society of Hematology (ASH) meeting in Orlando Florida? With three new drugs approved just before the start of the conference, there is so much to understand and absorb. Listen to Dr. Orlowski, MD, PhD of the MD Anderson Cancer Center give a simple explanation of the improvements in myeloma and some of his top takeaways in myeloma research. 

    Special thanks to our episode sponsor, Amgen.

  • 01:03

    Myeloma Crowd Radio: Dr. Djordje Atanackovic, MD, Huntsman Cancer Institute

    in Health

    With the explosion in immunotherapies for multiple myeloma, we have heard there are "windows" of best and most effective use. What are those windows and when is the best time to use these new approaches? The field is ever growing and Dr. Djordje Atanackovic will share how and when to use these new tools for a myeloma patient's best care. 

    Thanks to our episode sponsor, Takeda Oncology

  • Myeloma Crowd Radio: Dr. Daniel Fowler, MD, NIH

    in Health

    Immunotherapies are making their way into the clinic and as they do, more exciting options will be available for patients. Researchers are now studying the best possible way to leverage the standard and effective multiple myeloma treatments with ways to empower the immune system to fight myeloma. Learn what Dr. Daniel Fowler, MD of the NIH is doing to use a Th1 and Th2 immune therapy treatment in combination with stem cell transplant in an early clinical trial. 

    Special thanks to our Myeloma Crowd Radio episode sponsor, Amgen.

  • 01:06

    Myeloma Crowd Radio: Dr. Tomer Mark, MD, MSc, Weill Cornell Medical Center

    in Health

    Treatment for multiple myeloma is all about the combinations. Recently we've been hearing about the "BIRD" combinations. What are they and how effective are they? Learn from Dr. Tomer Mark, MD, MSc from Weill Cornell Medical Center about this new combination and what it means for myeloma patients. 

  • 01:02

    Myeloma Crowd Radio: Dr. Paul Shami, MD, Huntsman Cancer Institute

    in Health

    JSK is the first in its class with a new and unique method of killing multiple myeloma. It has a broad-spectrum anti-cancer activity, especially for myeloma and AML (acute myeloid leukemia) but is not toxic for normal cells. The JSK product is running through the standard approval process and is now in an advanced stage of pre-clinical development. Orphan drug designation has been obtained for myeloma and toxicology studies are now in the planning stages. JSK is active against drug-resistant myeloma cells and could be use with bortezomib to treat multiple myeloma. Dr. Paul Shami, MD of the Huntsman Cancer Institute joins us to describe the develoment and use of this new treatment now in development.

    Thanks to our episode sponsor, Takeda Oncology. 

  • 01:20

    Myeloma Crowd Radio: Dr. Don Benson, MD, PhD, Ohio State University

    in Health

    Dr. Don Benson, MD, PhD of The James Cancer Center at Ohio State University is a multiple myeloma specialist with deep expertise in immunotherapy. He shares the growing and exciting world of immunotherapies in multiple myeloma - how they work and how they are opening up an exciting new set of opportunities for myeloma patients.

  • 00:59

    Myeloma Crowd Radio: Dr. Adam Cohen, MD, Perelman Center for Advanced Medicine

    in Health

    The University of Pennsylvania had tremendous results with a recent clinical trial using a CAR T cell treatment targeting CD19 for a myeloma patient. The results were so impressive that some wonder if they have been able to eliminate the myeloma stem cell clone for one patient who had relapsed 9 therapies and had a high-risk genetic feature. Learn more about this success and where UPENN is going next using CAR therapy with Dr. Adam Cohen, MD, Director of Myeloma Immunotherapy at the Perelman Center for Advanced Medicine at UPENN.

    Thanks to our episode sponsor, Amgen.

  • 01:23

    Myeloma Crowd Radio: Dr. Jens Hillengass, MD, University of Heidelberg

    in Health

    Could an MRI predict how a multiple myeloma patient's disease will progress and respond to treatment? Learn what Dr. Jens Hillengass, MD of the University of Heidelberg is doing to use the latest in imaging techniques to learn more about an individual patient's myeloma and what it means for their outcomes and care. 

  • 01:15

    Myeloma Crowd Radio: Dr. Mike Thompson, MD, PhD, Aurora Health Care

    in Health

    Social media tools can be used by doctors and patients to speed the time to cure, especially for rare diseases like multiple myeloma. Learn from myeloma specialist and oncologist Dr. Mike Thompson, MD, PhD from the Aurora Health Care how he is driving social media adoption in oncology to increase the speed for the discovery of a cure and what that means in the every day lives of myeloma patients.

    Special Thanks to today's episode sponsor, Takeda Oncology.